APOA1 and chronic myelogenous leukemia, BCR-ABL1 positive: In addition, there might be a synergistic effect in CIGB-258 and HDL to inhibit CML toxicity by increasing HDL and apoA-I stability and PON activity, as shown in Figure 1, Figure 2 and Figure 3.